Each ROVATOR® 10 film-coated tablet contains Rosuvastatin calcium equivalent to Rosuvastatin 10 mg
Each ROVATOR® 20 film-coated tablet contains Rosuvastatin calcium equivalent to Rosuvastatin 20 mg
- Rosuvastatin is a selective and competitive HMG-CoA reductase inhibitor, a rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a cholesterol precursor. Rosuvastatin’s main site of action is in the liver, the target organ for lowering cholesterol. Rosuvastatin increases the number of hepatic LDL receptors on the cell surface, enhances LDL uptake and catabolism and inhibits hepatic VLDL synthesis thereby reducing the total number of VLDL and LDL particles.
- Rosuvastatin reduces high LDL cholesterol, total cholesterol, triglycerides, and increases HDL cholesterol. Rosuvastatin also lowers ApoB, non-HDL cholesterol, VLDL cholesterol, VLDL-TG and increases ApoA-1. Rosuvastatin also reduced the ratio of LDL cholesterol/HDL cholesterol, total HDL cholesterol/cholesterol and non-HDL/HDL cholesterol and ApoB/ApoA-1 cholesterol.
- Therapeutic response to Rosuvastatin is seen within 1 week of initiation of therapy and the maximum 90% response is usually achieved within 2 weeks. Maximum response is usually achieved within 4 weeks and maintained thereafter.
- Rosuvastatin is recommended for patients with primary hypercholesterolemia (Type IIa) or dyslipidemia (Type IIb) as a dietary adjunct if the response to diet and exercise is inadequate.
- Rosuvastatin reduces high LDL cholesterol, total cholesterol, triglycerides and ApoB, and increases HDL cholesterol.
The recommended initial dose is 5 or 10 mg once daily, either in statin-naive patients or in patients switching from another HMG-CoA inhibitor. The choice of initial dose should take into account the individual patient’s cholesterol level and future cardiovascular risk and potential risk of side effects. Dosage adjustments to the next dose level can be made after 4 weeks, if needed. Given the increased reported rate of adverse events at 40 mg compared to lower doses, administration of a maximum dose of 40 mg should only be considered in patients with severe hypercholesterolemia at high cardiovascular risk (especially certain doses with familial hypercholesterolemia), who do not achieve their treatment goals with low doses. 20 mg, and in patients who will be followed up routinely. Supervision by an expert doctor is recommended when starting a dose of 40 mg.
Presentation and Registration Number:
ROVATOR® 10 Film Coated Tablets Box, 3 strips @ 10 film coated tablets No. Reg. : DKL1608023817A1
ROVATOR® 20 Film Coated Tablets Box, 3 strips @ 10 film coated tablets No. Reg. : DKL1608023817B1
ON MEDICAL PRESCRIPTION ONLY
This post was written by admin